Psagot Investment House Ltd. Sells 250 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Psagot Investment House Ltd. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 585 shares of the biopharmaceutical company’s stock after selling 250 shares during the period. Psagot Investment House Ltd.’s holdings in Gilead Sciences were worth $38,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in GILD. Eads & Heald Wealth Management bought a new position in shares of Gilead Sciences in the 1st quarter worth about $201,000. Kempen Capital Management N.V. raised its position in shares of Gilead Sciences by 4.3% in the 1st quarter. Kempen Capital Management N.V. now owns 360,584 shares of the biopharmaceutical company’s stock worth $23,304,000 after acquiring an additional 14,814 shares in the last quarter. Letko Brosseau & Associates Inc. raised its position in shares of Gilead Sciences by 11.2% in the 1st quarter. Letko Brosseau & Associates Inc. now owns 1,264,156 shares of the biopharmaceutical company’s stock worth $81,702,000 after acquiring an additional 126,918 shares in the last quarter. Brandes Investment Partners LP grew its stake in shares of Gilead Sciences by 33.5% in the 1st quarter. Brandes Investment Partners LP now owns 30,924 shares of the biopharmaceutical company’s stock valued at $2,026,000 after buying an additional 7,765 shares during the period. Finally, Lido Advisors LLC grew its stake in shares of Gilead Sciences by 53.0% in the 1st quarter. Lido Advisors LLC now owns 46,168 shares of the biopharmaceutical company’s stock valued at $2,984,000 after buying an additional 15,994 shares during the period. 76.78% of the stock is owned by institutional investors and hedge funds.

Shares of GILD stock opened at $68.41 on Thursday. The firm’s fifty day simple moving average is $67.84. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.37 and a quick ratio of 1.18. Gilead Sciences, Inc. has a 1 year low of $56.56 and a 1 year high of $77.25. The company has a market cap of $85.80 billion, a PE ratio of 9.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, beating analysts’ consensus estimates of $2.06 by $0.02. The firm had revenue of $6.42 billion during the quarter, compared to analyst estimates of $6.78 billion. Gilead Sciences had a net margin of 1.18% and a return on equity of 51.91%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.05 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 29th. Investors of record on Tuesday, June 15th were given a $0.71 dividend. The ex-dividend date of this dividend was Monday, June 14th. This represents a $2.84 annualized dividend and a yield of 4.15%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.06%.

In related news, Director Richard James Whitley sold 20,282 shares of the company’s stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $64.57, for a total value of $1,309,608.74. Following the completion of the transaction, the director now directly owns 51,404 shares in the company, valued at $3,319,156.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.12% of the stock is currently owned by insiders.

Several analysts have recently commented on GILD shares. TheStreet upgraded Gilead Sciences from a “c” rating to a “b-” rating in a research note on Tuesday, March 30th. Redburn Partners upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a research note on Tuesday, March 30th. Sanford C. Bernstein upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Thursday, April 1st. SVB Leerink lifted their price target on Gilead Sciences from $72.00 to $74.00 and gave the company an “outperform” rating in a research note on Friday, April 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Friday, May 7th. Ten research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $99.22.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Read More: Backdoor Roth IRA

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.